The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application.

Kexuan Yu,Yiqin Wang

doi:10.3389/pore.2021.1609906

Abstract

The annually increasing incidence of endometrial cancer in younger women has created a growing demand for fertility preservation. However, the diverse therapeutic efficacy among patients under the same histological subtype and the same tumor grade suggests the potential interference of the innate molecular characteristics. The molecular classification has now been applied in clinical practice and might help to stratify the endometrial cancer patients and individualize the therapy, but the candidates for the fertility-spared treatment are most likely to be subdivided in the subgroup lacking the specific signature. KRAS mutation has been linked to the malignant transition of the endometrium, while its role in molecular classification and fertility preservation is vague. Here, we mainly review the advance of molecular classification and the role of KRAS in endometrial cancer, as well as their correlation with fertility-preservation treatment.

Highlights

Endometrial cancer (EC) ranks as the second most common malignancy originating from the female reproductive tract, the incidence of which in the population between 20 and 44 years old is increasing globally and accounts for approximately 8.6% of all 417,367 new cases [1]
Patients suitable for the fertility-spared treatment are most likely subdivided into the molecular subtype of which the specific molecular signatures are Abbreviations: EC, endometrial cancer; EEC, endometrioid endometrial cancer
The Kirsten rat sarcoma viral oncogene homolog (KRAS) represents the most prevalent oncogene in human cancers, the mutation of which is reported to predict the carcinogenesis as well as the invasive progression of type I EC [3], suggesting that KRAS might be applied as a potential monitoring target for the fertility-preservation treatment of the early stage type I EC

Summary

KeXuan Yu and Yiqin Wang *

The annually increasing incidence of endometrial cancer in younger women has created a growing demand for fertility preservation. The molecular classification has been applied in clinical practice and might help to stratify the endometrial cancer patients and individualize the therapy, but the candidates for the fertility-spared treatment are most likely to be subdivided in the subgroup lacking the specific signature. KRAS mutation has been linked to the malignant transition of the endometrium, while its role in molecular classification and fertility preservation is vague. We mainly review the advance of molecular classification and the role of KRAS in endometrial cancer, as well as their correlation with fertility-preservation treatment.

INTRODUCTION

Yu and Wang

THE CONSERVATIVE TREATMENT OF EC

THE MOLECULAR CLASSIFICATION OF EC

Findings

Other codons